middle.news
Dimerix Secures $107M Japan Deal as ACTION3 Trial Hits Key Milestone
7:03pm on Monday 2nd of June, 2025 AEST
•
Biopharmaceutical
Read Story
Dimerix Secures $107M Japan Deal as ACTION3 Trial Hits Key Milestone
7:03pm on Monday 2nd of June, 2025 AEST
Key Points
Development and license agreement with Fuso Pharmaceutical worth up to ¥10.5 billion (~AU$107 million)
Completed recruitment for Part 2 of ACTION3 Phase 3 trial with 154 patients randomized
Received $7.9 million R&D tax incentive rebate boosting cash reserves
Cash position of AU$21.11 million at quarter end, excluding upcoming milestone payments
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE